Advertisement
Home Day 1

Day 1

Organ Involvement, GVHD Severity Predict Ruxolitinib Failure in Chronic GVHD

In updated results from a real-world analysis presented at the 2021 ASH Annual Meeting, researchers confirmed that ruxolitinib is an effective treatment...

A Study Looks at Unplanned Health Care Resource Utilization Among CAR T-Cell Therapy Recipients

While chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic cancers, it may lead to higher...

In a Real-World Analysis, CLL Treatment Has Shifted from Chemoimmunotherapy to Targeted Therapies

An analysis of real-world data regarding the treatment of patients with chronic lymphocytic leukemia (CLL) revealed that standards of care are shifting...

Venetoclax-Based Time-Limited Combination Treatments Versus Standard Therapy in Frontline CLL

A study presented at the 2021 American Society of Hematology Annual Meeting aimed to assess the efficacy and safety of three regimens...
Advertisement
Advertisement